This article is more than 5 years old. Information may no longer be current.
Latest Iluvien data similar to trial results
Patients with chronic diabetic macular edema treated with an Iluvien implant experienced an average visual acuity increase from 51.9 letters at baseline to 57.2 letters at 24-month follow-up, with IOP-related adverse events occurring at a similar frequency as those reported in the FAME study.
Fourteen United Kingdom clinics contributed data comparing real-world safety and visual function outcomes in eyes treated with an Iluvien implant (0.2µg per day fluocinolone acetonide, Alimera Sciences). Three hundred forty-five eyes of 305 patients with chronic DME had a mean follow-up of 428 days.
IOP-lowering drops were required in 13.9% of patients, 7.2% had IOP elevation of more than 30 mm Hg, and 0.3% required glaucoma surgery.
At 18 months, there was a 24.4% incidence of IOP increase of 10 mm Hg or more and a 13.4% rate of IOP elevation above 30 mm Hg. The IOP rates were similar to the FAME study outcomes at equivalent timepoints, 24.9% and 10.5%, respectively, according to the study.
At 24 months, 20.8% of patients had a 15 letter or greater improvement in visual acuity, and mean central subfield foveal thickness decreased from 451.2 µm to 355.5 µm. – by Robert Linnehan
Disclosures: Bailey reports she is a consultant for Allergan, Alcon, Bayer, Alimera Sciences, Roche and Novartis. Please see the study for all other authors’ relevant financial disclosures.